DBV submits FDA BLA for VIASKIN Peanut Patch in children aged 4-7
DBV Technologies submitted a BLA to the FDA for its VIASKIN Peanut Patch in children aged 4-7, seeking Priority Review; the FDA previously granted Breakthrough Therapy designation.
DBV Technologies submitted a BLA to the FDA for its VIASKIN Peanut Patch in children aged 4-7, seeking Priority Review; the FDA previously granted Breakthrough Therapy designation.